Table of Contents
1 Introduction
1.1 Definition
1.2 Scope of Study
1.3 Research Objective
1.4 Assumptions & Limitations
1.5 Market Structure
2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3 Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
3.5 Macroeconomic Indicators
4 Market Factor Analysis
4.1 Porter’s five forces model
4.1.1 Bargaining Power of suppliers
4.1.2 Bargaining Power of Customer
4.1.3 Intensity of Competitor’s
4.1.4 Threat of New Entrants
5 Global anti-asthma drugs market, by type
5.1 Introduction
5.1.1 Allergic (extrinsic)
5.1.2 Non-allergic (intrinsic) asthma
6 Global anti-asthma drugs market, by trigger
6.1 Introduction
6.1.1 Child-onset asthma
6.1.2 Adult-onset asthma
6.1.3 Exercise-induced asthma
6.1.4 Cough-induced asthma
6.1.5 Occupational asthma
6.1.6 Nocturnal asthma
6.1.7 Steroid-resistant asthma
7 Global anti-asthma drugs market, by drug class
7.1 Introduction
7.1.1 Bronchodilators (beta agonists, anti-cholinergics, xanthines)
7.1.2 Leukotriene antagonists
7.1.3 Mast cell stabilizers
7.1.4 Corticosteroids
7.1.5 Monoclonal antibody
7.1.6 Others
8 Global anti-asthma drugs market, by therapy
8.1 Introduction
8.1.1 Preventive
8.1.2 Curative
9 Global anti-asthma drugs market, by route of administration
9.1 Introduction
9.1.1 Oral
9.1.2 Inhaled
9.1.3 Intravenous
9.1.4 Subcutaneous
10 Global anti-asthma drugs market, by Regions
10.1 Introduction
10.1.1 Americas
10.1.1.1 North America
10.1.1.2 South America
10.1.2 Europe
10.1.2.1 Germany
10.1.2.2 France
10.1.2.3 UK
10.1.2.4 Italy
10.1.2.5 Spain
10.1.2.6 Rest of Europe
10.1.3 Asia Pacific
10.1.3.1 Japan
10.1.3.2 China
10.1.3.3 India
10.1.3.4 Republic of Korea
10.1.3.5 Rest of Asia Pacific
10.1.4 Middle East & Africa
11 Company Landscape
11.1 Introduction
11.1.1 Mergers Acquisitions
11.1.2 Collaborations
11.1.3 Release/New Product Launch
11.1.4 Other (Expansion, Updates, Partnership)
12 Company Profile
12.1 GlaxoSmithKline plc.
12.1.1 Company Overview
12.1.2 Product/Business Segment Overview
12.1.3 Financials
12.1.4 Key Developments
12.1.5 SWOT Analysis
12.2 Merck & Co., Inc.
12.2.1 Overview
12.2.2 Product/Business Segment Overview
12.2.3 Financials
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 AstraZeneca plc.
12.3.1 Overview
12.3.2 Product/Business Segment Overview
12.3.3 Financials
12.3.4 Key Developments
12.3.5 SWOT Analysis
12.4 F. Hoffmann-La Roche Ltd
12.4.1 Overview
12.4.2 Product/Business Segment Overview
12.4.3 Financials
12.4.4 Key Developments
12.4.5 SWOT Analysis
12.5 Teva Pharmaceutical Industries
12.5.1 Overview
12.5.2 Product/Business Segment Overview
12.5.3 Financials
12.5.4 Key Developments
12.5.5 SWOT Analysis
12.6 Novartis International AG
12.6.1 Overview
12.6.2 Product/Business Segment Overview
12.6.3 Financials
12.6.4 Key Developments
12.6.5 SWOT Analysis
12.7 Boehringer Ingelheim
12.7.1 Overview
12.7.2 Product/Business Segment Overview
12.7.3 Financials
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.8 Sunovion Pharmaceuticals Inc.
12.8.1 Overview
12.8.2 Product/Business Segment Overview
12.8.3 Financials
12.8.4 Key Developments
12.8.5 SWOT Analysis
13 Others
14 Appendix
List of Tables
TABLE 1 GLOBAL ANTI-ASTHMA DRUGS MARKET, 2020-2027 (USD MILLION)
TABLE 2 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY TYPES, 2020-2027 (USD MILLION)
TABLE 3 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY TRIGGER, 2020-2027 (USD MILLION)
TABLE 4 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
TABLE 5 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY THERAPY, 2020-2027 (USD MILLION)
TABLE 6 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)
TABLE 7 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY REGION, 2020-2027 (USD MILLION)
